Investigation of Ivs14+1G>A Polymorphism of Dpyd Gene in a Group of Bosnian Patients Treated with 5-Fluorouracil and Capecitabine
Adverse drug reactions still pose an important clinical problem. Dihydropyrimidine dehydrogenase (DPD) is an enzyme that regulates 5-FU quantities available for anabolic processes and hence affects its pharmacokinetics, toxicity and efficacy. There are several studies describing a hereditary (phar...
Main Authors: | Timur Cerić, Nermina Obralić, Lejla Kapur-Pojskić, Draženka Macić, Semir Bešlija, Anes Pašić, Šejla Cerić |
---|---|
Format: | Article |
Language: | English |
Published: |
Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
2010-05-01
|
Series: | Biomolecules & Biomedicine |
Subjects: | |
Online Access: | https://www.bjbms.org/ojs/index.php/bjbms/article/view/2712 |
Similar Items
-
Discovering novel germline genetic variants linked to severe fluoropyrimidine-related toxicity in- and outside DPYD
by: Jonathan E. Knikman, et al.
Published: (2024-08-01) -
Importance of Rare DPYD Genetic Polymorphisms for 5-Fluorouracil Therapy in the Japanese Population
by: Eiji Hishinuma, et al.
Published: (2022-06-01) -
Clinical Relevance of Novel Polymorphisms in the Dihydropyrimidine Dehydrogenase (<i>DPYD</i>) Gene in Patients with Severe Fluoropyrimidine Toxicity: A Spanish Case-Control Study
by: Paula Soria-Chacartegui, et al.
Published: (2021-11-01) -
DPYD variant testing in candidates for fluoropyrimidine treatment: A study protocol
by: Ana Hernández-Guío, et al.
Published: (2021-05-01) -
Ethnic Diversity of DPD Activity and the DPYD Gene: Review of the Literature
by: White C, et al.
Published: (2021-12-01)